Docetaxel is under clinical development by Nanology and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC). According to GlobalData, Phase II drugs for Muscle Invasive Bladder Cancer (MIBC) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Docetaxel’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Docetaxel overview

Docetaxel is under development for the treatment of muscle-invasive bladder cancer, non-muscle invasive bladder cancer, breast cancer, prostate carcinoma, urothelial carcinoma and renal cell carcinoma. The drug candidate is a sterile nanoparticle suspension which is administered intratumorally and intravascularly. The drug candidate is developed based on naked nanoparticle platform technology. It acts by targeting tubulin.It was also under development for treatment of breast cancer.

Nanology overview

Nanology operates as a clinical-stage oncology company. It offers a technology platform for the treatment of cancer and other serious illnesses. The company produces LSAMs in multiple drug classes including taxanes, cisplatin, TKIs and PARPIs. Its program includes clinical trials in ovarian, prostate and pancreatic cancers, pancreatic cysts, cutaneous metastases and actinic keratosis. The company operates its offices in Fort Worth and serves across the US. Nanology is headquartered in Fort Worth, Texas, the US.

For a complete picture of Docetaxel’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.